CD8A and neoplasm: The concurrent administration of oxaliplatin (~10 mg/kg) plus a PD-L1 blocker to mice bearing subcutaneous CT26 CRCs also failed to significantly affect tumor growth and did not improve the intratumoral or systemic ratio between CD8+ T cells and immunosuppressive CD4+CD25+FOXP3+ regulatory T (TREG) cells [28, 91], indicating that additional immunostimulatory molecules, such as TLR7 agonists, may be required to enable this therapeutic interaction [26].